OncoLens
OncoLens develops technologies that improve cancer treatment planning, simplify tumor board management, facilitate survivorship care planning, and automate accreditation and quality reporting through an intelligent workflow engine that streamlines business processes and enables more informed clinical decision-making.
OncoLens
OncoLens develops technologies that improve cancer treatment planning, simplify tumor board management, facilitate survivorship care planning, and automate accreditation and quality reporting through an intelligent workflow engine that streamlines business processes and enables more informed clinical decision-making.
TL;DR
What they do: AI-enabled oncology software for tumor boards, care planning, trial matching, registry automation, and analytics
Headquarters: Atlanta, Georgia
Founders / leadership: Anju Mathew (Founder & CEO), Dr. Lijo Simpson (Co-founder & CMO)
Employee count: 29
Latest funding: Series B, $16M announced Oct 24, 2024
Total funding: $27,850,000 (USD)
Company Overview
Problem Domain
Oncology clinical workflows, tumor board coordination, clinical trial matching, and registry/accreditation reporting
Founded
2016
Industry
Healthtech / Oncology software
Funding Track Record
$7,250,000
Participation from Martin Ventures and SeedToB Capital
$16,000,000
Martin Ventures and SeedToB Capital participated
Investor Signal
“Backed by specialized healthcare and impact-focused VCs including repeat investment from BIP Capital, Martin Ventures, and SeedToB Capital”